XTL Biopharmaceuticals Ltd. reported audited consolidated earnings results for the full year ended December 31, 2016. For the year, operating loss was $2,561,000 against $3,611,000 a year ago. Loss from continuing operations was $2,545,000 against $3,622,000 a year ago. Loss for the period attributable to equity holders of the company was $2,545,000 against $4,313,000 a year ago. Basic and diluted loss per share from continuing operations was $0.009 against $0.014 a year ago. Loss per share for the period was $0.009 against $0.017 a year ago.